↓ Skip to main content

Concise review: Adult mesenchymal stromal cell therapy for inflammatory diseases: How well are we joining the dots?

Overview of attention for article published in Stem Cells, June 2013
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (81st percentile)
  • Good Attention Score compared to outputs of the same age and source (79th percentile)

Mentioned by

twitter
8 tweeters
facebook
1 Facebook page

Citations

dimensions_citation
92 Dimensions

Readers on

mendeley
107 Mendeley
citeulike
1 CiteULike
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Concise review: Adult mesenchymal stromal cell therapy for inflammatory diseases: How well are we joining the dots?
Published in
Stem Cells, June 2013
DOI 10.1002/stem.1452
Pubmed ID
Authors

Griffin, Matthew D., Elliman, Stephen J., Cahill, Emer, English, Karen, Ceredig, Rhodri, Ritter, Thomas, Elliman, Stephen J, Griffin MD, Elliman SJ, Cahill E, English K, Ceredig R, Ritter T

Abstract

Mesenchymal stromal (stem) cells (MSCs) continue to be a strong area of focus for academic- and industry-based researchers who share the goal of expanding their therapeutic use for diverse inflammatory and immune-mediated diseases. Recently, there has been an accelerated rate of scientific publication, clinical trial activity, and commercialisation in the field. This has included the reporting of exciting new developments in four areas that will be of key importance to future successful use of MSC-based therapies in large numbers of patients: (a) fundamental biology of the primary cells in bone marrow and other tissues that give rise to MSCs in culture. (b) Mechanisms by which MSCs modulate immune and inflammatory responses in vivo. (c) Insights into MSC kinetics, safety, and efficacy in relevant animal disease models. (d) Isolation, definition, and clinical trial-based testing of human MSCs by biomedical companies and academic medical centers. Despite this progress, it remains unclear whether MSCs will enter mainstream therapeutic practice as a frequently used alternative to pharmacotherapy or surgical/radiological procedures in the foreseeable future. In this review, we summarize some of the most significant new developments for each of the four areas that contribute to the process of translating MSC research to the clinical arena. In the context of this recent progress, we discuss key challenges and specific knowledge gaps which, if not addressed in a coordinated fashion, may hinder the creation of robust "translational pipelines" for consolidating the status of MSC-based therapies.

Twitter Demographics

The data shown below were collected from the profiles of 8 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 107 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Ireland 2 2%
Germany 1 <1%
Netherlands 1 <1%
Australia 1 <1%
United Kingdom 1 <1%
United States 1 <1%
Unknown 100 93%

Demographic breakdown

Readers by professional status Count As %
Researcher 29 27%
Student > Ph. D. Student 25 23%
Student > Master 13 12%
Student > Doctoral Student 10 9%
Student > Bachelor 7 7%
Other 19 18%
Unknown 4 4%
Readers by discipline Count As %
Agricultural and Biological Sciences 38 36%
Medicine and Dentistry 29 27%
Biochemistry, Genetics and Molecular Biology 8 7%
Immunology and Microbiology 7 7%
Engineering 4 4%
Other 14 13%
Unknown 7 7%

Attention Score in Context

This research output has an Altmetric Attention Score of 7. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 15 June 2015.
All research outputs
#2,581,136
of 14,125,289 outputs
Outputs from Stem Cells
#842
of 3,358 outputs
Outputs of similar age
#28,777
of 153,729 outputs
Outputs of similar age from Stem Cells
#6
of 29 outputs
Altmetric has tracked 14,125,289 research outputs across all sources so far. Compared to these this one has done well and is in the 81st percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,358 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 7.7. This one has gotten more attention than average, scoring higher than 74% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 153,729 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 81% of its contemporaries.
We're also able to compare this research output to 29 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 79% of its contemporaries.